Review Article

Autoimmune Hemolytic Anemia

Durga Krishnan*, Noorul Ameen S**, Aravind CS***, Balaji R***

*Professor, **Associate Professor, ***Senior Resident, Chettinad hospital and research institute, Chettinad Academy of Research & Education, Chennai, India.

Corresponding author - Durga Krishnan (drdurga79@gmail.com)

Chettinad Health City Medical Journal 2017; 6(2): 52 - 59

Dr Durga did her undergraduation and postgraduation from Mahatma Gandhi Memorial Medical College, Indore. Her area of interest is Cardiology

Abstract

Autoimmune hemolytic anemia (AIHA) is caused by autoantibodies that react with Red Blood Cells. It is an uncommon entity. Even being a well-recognized entity for so many years, there are lot of difficulties regarding its diagnosis and therapies used for treatment. There are different types of autoimmune hemolytic anemia like warm antibody hemolytic anemia, cold agglutinin disease/paroxysmal cold hemoglobinuria and mixed type. The warm antibodies react at temperatures ≥37°C and cold agglutinin disease/paroxysmal cold hemoglobinuria react at <37°C. Usually the hemolysis is extravascular. The positive direct antiglobulin (direct Coombs) test establishes the diagnosis and may suggest the cause. Treatment is usually cause dependent and includes corticosteroids, splenectomy, IV immune globulin, immunosuppressants and withdrawal of drugs.

Key Words: Autoimmune hemolytic anemia, AIHA, Autoantibodies, Warm Antibody, Cold Antibody, Mixed AIHA.

Introduction

Autoimmune hemolytic anemia (AIHA) is a group of disorders characterized by an impairment of the immune system which produces auto-antibodies (auto erythrocytes antibodies AEA), that act against one’s own red blood cells considering it as foreign substance to the body. The main feature in immune related RBC injury is decreased RBC survival in-vivo along with confirmation of host antibodies that react with heterologous RBCs. AIHA can be primary or idiopathic and secondary. Secondary AIHA could be due to infections, autoimmune diseases, lymphoma or lympho-proliferative disorder and drugs. To establish these antibodies, the test used is direct antiglobulin test (DAT), also known by another name as Coombs test. A negative Coombs test does not exclude AIHA.

Etiopathogenesis

I. Warm-autoantibody (WA) type: autoantibody maximally active at body temperature (37°C)
   A. Primary or idiopathic warm AIHA
   B. Secondary warm AIHA
      1. Associated with lymphoproliferative disorders (e.g., Hodgkin disease, CLL, lymphoma)
      2. Associated with certain nonlymphoid neoplasms (e.g., ovarian tumors)
      3. Associated with the rheumatic disorders, particularly SLE
      4. Associated with certain chronic inflammatory diseases (e.g., ulcerative colitis)
      5. Associated with ingestion of certain drugs (e.g., -methyl) dopa
   II. Cold-autoantibody (CA) type: autoantibody optimally active at temperatures <37°C
      A. Mediated by cold agglutinin
         1. Idiopathic (primary) chronic cold agglutinin disease
         2. Secondary cold agglutinin hemolytic anemia

Table 1 - Classification of Hemolytic Anemia as a Result of Immune Injury

<table>
<thead>
<tr>
<th>Type</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>I. Warm autoantibody (WA) type</td>
<td></td>
</tr>
<tr>
<td>A. Primary or idiopathic warm AIHA</td>
<td></td>
</tr>
<tr>
<td>B. Secondary warm AIHA</td>
<td></td>
</tr>
<tr>
<td>1. Associated with lymphoproliferative disorders (e.g., Hodgkin disease, CLL, lymphoma)</td>
<td></td>
</tr>
<tr>
<td>2. Associated with certain nonlymphoid neoplasms (e.g., ovarian tumors)</td>
<td></td>
</tr>
<tr>
<td>3. Associated with the rheumatic disorders, particularly SLE</td>
<td></td>
</tr>
<tr>
<td>4. Associated with certain chronic inflammatory diseases (e.g., ulcerative colitis)</td>
<td></td>
</tr>
<tr>
<td>5. Associated with ingestion of certain drugs (e.g., -methyl) dopa</td>
<td></td>
</tr>
<tr>
<td>II. Cold autoantibody (CA) type</td>
<td></td>
</tr>
<tr>
<td>A. Mediated by cold agglutinin</td>
<td></td>
</tr>
<tr>
<td>1. Idiopathic (primary) chronic cold agglutinin disease</td>
<td></td>
</tr>
<tr>
<td>2. Secondary cold agglutinin hemolytic anemia</td>
<td></td>
</tr>
<tr>
<td>a. Postinfectious (e.g., Mycoplasma pneumoniae or infectious mononucleosis)</td>
<td></td>
</tr>
<tr>
<td>b. Associated with malignant B cell lymphoproliferative disorder</td>
<td></td>
</tr>
<tr>
<td>B. Mediated by cold hemolysins</td>
<td></td>
</tr>
<tr>
<td>1. Idiopathic (primary) paroxysmal cold hemoglobinuria (very rare)</td>
<td></td>
</tr>
<tr>
<td>2. Secondary</td>
<td></td>
</tr>
<tr>
<td>a. Donath-Landsteiner hemolytic anemia, usually associated with an acute viral syndrome in children (relatively uncommon)</td>
<td></td>
</tr>
<tr>
<td>b. Congenital or tertiary syphilis in adults (very rare)</td>
<td></td>
</tr>
<tr>
<td>III. Cold and warm autoantibodies</td>
<td></td>
</tr>
<tr>
<td>A. Primary or idiopathic mixed AIHA</td>
<td></td>
</tr>
<tr>
<td>B. Secondary mixed AIHA</td>
<td></td>
</tr>
<tr>
<td>1. Associated with the rheumatic disorders, particularly SLE</td>
<td></td>
</tr>
<tr>
<td>IV. Drug-immune hemolytic anemia</td>
<td></td>
</tr>
<tr>
<td>A. Hapten or drug adsorption mechanism</td>
<td></td>
</tr>
<tr>
<td>B. Ternary (immune) complex mechanism</td>
<td></td>
</tr>
<tr>
<td>C. True autoantibody mechanism</td>
<td></td>
</tr>
</tbody>
</table>

AIHA = Autoimmune hemolytic anemia; SLE = Systemic lupus erythematosus, CLL = Chronic Lymphocytic Leukemia

Warm antibodies

The destruction of red blood cells in hemolytic anemia is due to the presence of autoantibodies, mediated by immunoglobulins mainly IgG, IgM, or IgA which may depend upon on the complement. These auto-antibodies generally react at temperature of 37°C and cause warm AIHA. The activation of complement continues till the emergence and establishment of membrane attack complex (MAC) which leads to hemolysis. Very rarely these warm auto-antibodies can be IgM related but it is not detected in the serum; it
combines with the RBCs, activates the complement and separates from the membrane leaving only the complement⁴⁻⁶.

When the RBCs are coated with IgG along with or without complement (C₃c, C₃d), the phagocytosis takes place by Fc gamma receptor in the spleen, whereas if it is coated only with the complement (C₃c, C₃d) without IgG, it is eliminated by complement-receptor phagocytosis in the liver (extra-vascular hemolysis)⁹. In primary AIHA the only aberrant auto-antibody is anti erythrocyte auto antibody and it is specific for single RBCs membrane that is small range of auto-reactivity. In secondary AIHA (due to lymphoma, CLL (chronic lymphocytic leukemia), or SLE) the auto antibody are usually formed due to latent defect in immune system. The auto-antibodies formed secondary to drug is usually reversible on withdrawal of the drug⁴.

Cold antibodies
IgM auto-antibodies (usually monoclonal) are pentameric antibodies which after fixing with complement causes intravascular hemolysis and to a small extent C₃d mediated extra-vascular hemolysis. These antibodies react at low temperature with optimal effect at 4°C⁵⁻⁷.

The thermal range of IgM auto-antibodies is from 0°C–34°C and those antibodies which react at temperature close to physiological temperature are the most harmful and cause severe form of AIHA⁶⁻⁷. These auto-antibodies are usually confirmed by positive DAT. Sometimes DAT could be positive for both IgG and high titres of C₃d which shows that patient is having mixed type AIHA. In few cases DAT is negative and the patients present with severe form of disease which is refractory to treatment and has worst outcome⁹⁻¹⁰. These are usually IgM associated warm autoantibodies which can be tested by dual direct agglutination test (DDAT)⁹. At this juncture, it is worth mentioning Donath-Landsteiner autoantibody, which is a biphasic cold hemolysin, causing complement-mediated hemolysis and contributes to paroxysmal cold hemoglobinuria which is common in children and very rare in adults¹¹⁻¹².

Epidemiology
Hemolytic anemia represents approximately 5% of all anemias. Acute AIHA is relatively uncommon disease, with an incidence of 1-3 cases/100,000 population per year⁷. The prevalence of Cold agglutinin disease is 14 per million population⁶. The incidence of mixed autoimmune hemolytic anemia (both warm and cold) is approximately 1 in 80,000; and the occurrence of cold agglutinin disease is 1 in 300,000⁶⁻¹¹. Warm AIHA although a rare disease, can affect any age from infancy to old age but mostly common over the age of 40 years with peak incidence at the age of 70 years⁴. Not much is known about cold agglutinin disease, few reports say that it is more common in male children and female adults⁵⁻¹⁰⁻¹².

Diagnosis
The diagnosis of AIHA is mainly made by clinical presentation, lab findings and immune hematological diagnosis.

Clinical features of warm antibody associated AIHA
The features of warm AIHA are similar to that of any other hemolytic anemia. Usually the first presentation is jaundice along with other signs of anemia. These patients usually have mild to moderate splenomegaly. Those who presents with acute AIHA have severe anemia developing in short duration along with other profound features of anemia including hepatosplenomegaly, hyperapnea, tachycardia and even heart failure⁶⁻⁹. Whenever a patient presents with sudden onset anemia, jaundice and splenomegaly, suspect AIHA and search for the causes and mechanisms in such cases.

Clinical features of cold antibody AIHA
The patient with cold agglutinin AIHA (CA-AIHA) usually presents as chronic hemolytic anemia with or without jaundice. Some patients also complain of dark coloured urine due to hemoglobinuria which represents intravascular hemolysis. On exposure to cold, they develop acrocyanosis and veno-occlusive features of fingers, toes and tip of nose because of blockage of micro-circulation by lysed RBCs. Skin ulceration is uncommon. There could be additional features of other underlying diseases like respiratory involvement in mycoplasma pneumonia and splenomegaly in lymphoproliferative disorders⁶⁻¹². In paroxysmal cold hemoglobinuria, the patient develops features after exposure to cold.

Drug induced Immune Hemolytic Anemia
The presentation of drug induced AIHA is variable. Drugs whose auto reactivity depends upon hapten/drug adsorption (like penicillin) and autoimmunity (like methyldopa); and present with mild to moderate hemolysis. Other drugs like cephalosporins or quinidine whose autoimmune depend upon ternary complex mechanism present as sudden and severe hemolysis with hemoglobinuria. Sometimes patients may present with acute renal failure.

Laboratory findings
Severity of presentation of AIHA is variable. In warm AIHA, the compensated hemolytic anemia usually shows reticulocytosis. In some cases AIHA is associated with auto immune thrombocytopenia when it known as Evans syndrome. In CA-AIHA, the patient presents with mild to moderate anemia, the hematocrit is low but not less than 15%. There is sudden decrease in hematocrit in patients with paroxysmal cold hemoglobinuria during an attack. The presentation of drug induced hemolytic anemia is almost similar to Warm AIHA and the peripheral smear may reveal polychromasia, spherocytosis (unless proved otherwise it is taken as immune hemolytic anemia), RBCs fragments, nucleated RBCs and sometimes erythrophagocytosis by monocytes.

Next important is the presence of indirect hyper-bilirubinemia with only modest increase in total bilirubin and presence of urobilinogen. The level of haptoglobin is low and LDH level is usually increased, but if normal does not rule out hemolytic anemia. Fig 1 represents an algorithm for approach to AIHA.
Immunohematological diagnostics

The diagnosis of AIHA and drug immune hemolytic anemia depends upon the detection of auto antibodies against RBCs. Direct and indirect antiglobulin test (Coombs’s test) are done to demonstrate non-agglutinating red cell antibodies (indirect antiglobulin test, IAT) or sensitized red cells (direct antiglobulin test, DAT)\textsuperscript{22-24}.

There are three possible designs for direct antiglobulin test for AIHA and drug induced hemolytic anemia: one is RBCs coated with only IgG, second is RBCs coated with IgG and complement components, and third is RBCs coated with complement components without detectable immunoglobulin.

Reaction pattern and type of injury based on IgG and complement is shown in table 2.

| IgG alone | \begin{itemize} 
  \item i) Warm antibody autoimmune hemolytic anemia
  \item ii) Drug-immune hemolytic anemia: hapten drug adsorption type or autoantibody type.
\end{itemize} |
| Complement | \begin{itemize} 
  \item i) Warm antibody autoimmune hemolytic anemia with subthreshold IgG deposition.
  \item ii) Cold agglutinin disease.
  \item iii) Paroxymal cold hemoglobinuria
  \item iv) Drug-immune hemolytic anemia: ternary complex type
\end{itemize} |
| Both IgG and Complement | \begin{itemize} 
  \item i) Warm antibody autoimmune hemolytic anemia
  \item ii) Drug-immune hemolytic anemia: autoantibody type (rare)
\end{itemize} |

| Table 2 - Reaction pattern and type of injury based on IgG and complement |

Direct antiglobulin test (DAT) tests the presence of in vivo antibodies. On the addition of polyspecific anti-human globulin reagent to RBCs, the RBCs agglutinate and the test is considered as positive\textsuperscript{27,28}. Sometimes when the suspicion of AIHA is strong and the DAT is negative, the test should be repeated with anti-IgA, anti-IgM, anti-IgG, anti-C\textsubscript{3c} and anti-C\textsubscript{3d} separately, because the poly-specific anti human globulin contains only IgG, and C\textsubscript{3d}\textsuperscript{26,29}. If still the DAT remains negative, one should look for spherocytes in peripheral smear. When the DAT is positive with the polyspecific anti-human globulin reagent further testing with monospecific reagent is required to differentiate the type of auto-antibody whether it is IgM, IgG, IgA, C\textsubscript{3c}, or C\textsubscript{3d} (Fig 2). If antibody is negative and complement deposition is noticed, then one should think of CA-AIHA(IgM), WA-AIHA(IgM, IgA), or bithermic antibodies. Such situation warrants further laboratory investigations to ascertain the presence of either IgM or IgA\textsuperscript{5}.

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{Fig1.png}
\caption{Approach to Autoimmune hemolytic anemia (AIHA)}
\end{figure}

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{Fig2.png}
\caption{Direct antiglobulin test (DAT)\textsuperscript{5}}
\end{figure}
Tuberculosis

General

Blood transfusion: In general blood transfusion shall always be avoided as far as possible. If it is required and/or unavoidable, blood with least incompatibility should be selected and patients serum should be thoroughly checked for alloantibody which, if present, can lead to critical hemolytic transfusion reactions especially in patients with pregnancy and those who have received previous blood transfusion. If the patient is a non pregnant woman or in men without any prior history of transfusion, the chances of alloantibody are almost nil and they can go with transfusion after appropriate matching. For other cases, from the point of patient safety one has to go ahead with phenotyping for other subclasses of Rh, Kell, Kidd, Duffy, Ss. In emergencies and resource limited situations, it is worth to consider the usage of transfusion set with filters.

Treatment of WA-AIHA

First line therapy

Corticosteroids

The first line of treatment for WA-AIHA (primary) is corticosteroid (prednisolone). Algorithm for steroid treatment is shown in Fig. 5. Approximately 20% of patient with WA-AIHA show complete remission with steroid and 10% show no or minimal response. All patients with steroid therapy should receive supplementation of vitamin D, bisphosphonates, calcium and folic acid. In those who are unresponsive to initial therapy, secondary causes like malignant tumor, ovarian teratoma (benign), inflammatory bowel disease (mainly ulcerative colitis) and warm IgM AIHA should be considered.

Second line therapy

Patients who require more than 15mg of steroid/day and/or refractory to initial steroid treatment are candidates for second line regimen. There are many options for second line treatment with somewhat proven efficacy. The two options are Splenectomy and Rituximab. Algorithm for treatment of steroid refractory WA-AIHA is given in Fig. 6.
Fig 5: Algorithm for treatment of WA-AIHA with corticosteroids

**WA-AIHA**
- **Primary**
- **Prednisolone**
  - Dose: 1-1.5 mg/kg/day for three weeks
  - Adequate response (Increase in hematocrit and hemoglobin)
  - No response after 3 weeks
  - **Second Line therapy**
    - Decrease the dose to 30mg/day
    - Decrease @ 2.5-5mg/day every month
    - If patient is maintaining at low dose for >3 months
    - Withdraw steroid

- **Acute/Severe (Evan’s)**
  - **IV Methylprednisolone**
    - 100-200 mg in divided doses for 10-14 days
    - 500-1000mg once daily for three days
  - Response
  - No response

**Fig 6: Treatment of steroid refractory WA-AIHA**

- Steroid refractory WAHA
  - Less preferred
  - Splenectomy
  - Refractory or recurrent
  - (Low dose) steroids
  - Rituximab
  - Recurrent
  - Refractory
  - Retreatment with Rituximab
  - Insufficient response

- Rituximab
  - Refractory or recurrent
  - Splenectomy
  - Recurrent
  - Refractory
  - Retreatment with Rituximab
  - Insufficient response

- Other immunosuppressants or experimental therapy
Splenectomy
Most accepted second line regimen is splenectomy, but available data on duration of complete or partial remission after splenectomy are less. The factors favouring this regimen are better initial response and interim effectiveness. Long remission was noticed among those patients who underwent splenectomy with or without steroid therapy. The remission is approximately 38-82% depending upon the percentage of secondary cases which are less responsive. With the laparoscopic approach there is lesser chance of perioperative complications like pulmonary embolism, abscess, bleeding etc. Patients should be vaccinated against encapsulated organisms such as Pneumococcus, Meningococcus, and H.influenzae. The mortality rate after splenectomy is more in children as compared to adults. The cure rate is approximately 20%.

Rituximab
It is a monoclonal anti-CD20 antibody which acts on B lymphocytes. It also shows short term efficacy and is usually given in a dose of 375mg/m² in 4 doses for 4 weeks including the 1st, 8th, 15th, and 22nd day. The actual response rate is not known. It is efficacious in both warm and cold AIHA with complete response rate of about 54-60%. If the patient is on steroid, they are advised to continue the same until the response with rituximab has started. It shows good response when used as a monotherapy or in combination with other drugs like steroid, immunosuppressant, interferon α, irrespective of previous treatment. It is highly efficacious in patients with Evans syndrome. As such the drug is safe, and the long term side effects are progressive multifocal leukoencephalopathy. It is contraindicated in patients with untreated hepatitis B infection. Usually it is used in patients who refuse splenectomy or in whom the splenectomy is contraindicated.

Immunosuppressants
Azathioprine (dose 100 to 150mg/day) and Cyclophosphamide (100mg/day) can also be considered as second line therapy with response rate of 40-60%. Cyclosporine has also shown good response in patients with refractory warm AIHA. Only limited data is available for Mycophenolate mofetil which also showed good response in few studies.

Other modalities
Danazol, a synthetic anabolic steroid given with or after prednisolone is good for initial response, but less effective in refractory or relapse cases. Intravenous IG alone or in combination with corticosteroid is used mostly in children because of relatively less side effects. Plasmapheresis is used in warm AIHA in both children and adults in cases where steroid and transfusion are not able to control anemia on temporary basis.

Miscellaneous options
High dose Cyclophosphamide (50mg/kg/day for 4 days) along with GM-CSF have shown to be effective in highly refractory cases of WA-AIHA. Alentuzumab an anti CD52 antibody and Ofatumumab, an anti CD20 antibody are also under trials.

Treatment of secondary AIHA
In SLE, the treatment is same as primary AIHA. For patients with CLL, prednisolone is the first choice (also in fludarabine associated AIHA). In active CLL, additional chemotherapeutic agents (Chlorambucil, R-CVP) and in refractory cases, rituximab and splenectomy are indicated. For Non Hodgkins Lymphoma, chemotherapy with or without rituximab may give a sustained response.

Treatment of CA-AiHA
Cold AIHA are usually secondary in nature and associated with lympho-proliferative disorders like IgM associated monoclonal gammopathy. The treatment is usually reserved for symptomatic cases. In asymptomatic cases, it may be moderately helpful to keep the extremities warm to avoid symptoms. Transfusion can be safely done in these patients by taking needed precautions such as keeping the patient warm. The use of steroids and splenectomy are not much useful and discouraged nowadays. The era for the treatment of CA-AiHA has changed after the introduction of rituximab. The drug is helpful in treatment because it is specifically directed against B-cell clone which is the culprit in many patients. The patients who are refractory to one or two courses of rituximab, a combination of rituximab and fludarabine (40mg/m² on 1st and 5th day) have shown high response rate and long duration of remission. Cold AIHA secondary to infection is usually self limited and treating the underlying cause is sufficient.

Paroxysmal cold hemoglobinuria (PCH) is generally known to occur with Donath Landsteiner antibody of IgG type, pointing against the P blood group system. Though PCH was previously associated with syphilis, it is now associated with other viral and bacterial infections. This is also a self limiting condition but may sometimes need treatment with steroids and transfusion.

Conclusion
AIHA is a well known hematological condition, whose clinical features, pathophysiology and diagnosis have been extensively described in literature. The discovery of Rituximab has remarkably improved treatment outcomes of AIHA.

References


